Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR)
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
10:40am, Monday, 10'th Jun 2024
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
03:03am, Tuesday, 14'th May 2024
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2024 Earnings Call Transcript May 13, 2024 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Kristen Klusk
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
06:15pm, Monday, 13'th May 2024
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago.
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Monday, 13'th May 2024
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024–
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
09:15am, Thursday, 09'th May 2024
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO,
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
09:00am, Wednesday, 08'th May 2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
09:00am, Monday, 06'th May 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
09:00am, Wednesday, 24'th Apr 2024
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
10:56am, Wednesday, 10'th Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the posi
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
10:56am, Monday, 25'th Mar 2024
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Capricor Therapeutics to Present at Upcoming Investor Conferences
08:30am, Thursday, 21'st Mar 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventi
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
10:56am, Thursday, 07'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the posi
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
08:30am, Wednesday, 06'th Mar 2024
Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Presentation Highlights Positive 24-Month Results from HOPE-2 Open L
Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript
11:14pm, Thursday, 29'th Feb 2024
Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript
